A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Dr PK Bhavani, MBBS., MPH., PGDBEME
- Telefonnummer: 044 2836 9537
- E-mail: bhavani.pk@icmr.gov.in
Undersøgelse Kontakt Backup
- Navn: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Telefonnummer: 044 2836 9518
- E-mail: narendra.ng@icmr.gov.in
Studiesteder
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, Indien, 522503
- Rekruttering
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
Kontakt:
- Dr S Sathiyanarayanan, MBBS., MD
- Telefonnummer: 08645 280021
- E-mail: sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati, Assam, Indien, 781101
- Aktiv, ikke rekrutterende
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot, Gujarat, Indien, 360001
- Ikke rekrutterer endnu
- Govt. PDU Medical College
-
Kontakt:
- Dr Bhoomika Patel, MBBS., MD
- Telefonnummer: 0281 245 8337
- E-mail: doctorbhoomika@gmail.com
-
Surat, Gujarat, Indien, 395001
- Aktiv, ikke rekrutterende
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400008
- Rekruttering
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
Kontakt:
- Dr Priti Meshram, MBBS., MD., DNB
- Telefonnummer: 022 2373 5555
- E-mail: drpritimeshram@gmail.com
-
Nagpur, Maharashtra, Indien
- Ikke rekrutterer endnu
- All India Institute Of Medical Sciences, Nagpur
-
Kontakt:
- Dr Yogesh Bahurupi, MBBS., MD
- Telefonnummer: 0712 2352078
- E-mail: dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong, Meghālaya, Indien, 793018
- Rekruttering
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
Kontakt:
- Dr Monaliza Lyngdoh, MBBS., MD
- Telefonnummer: 0364 2538013
- E-mail: monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indien, 110030
- Ikke rekrutterer endnu
- National Institute of TB and Respiratory Diseases
-
Kontakt:
- Dr Jitendra Kumar Saini, MBBS., MD
- Telefonnummer: 011 2651 3325
- E-mail: drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar, Odisha, Indien, 751019
- Aktiv, ikke rekrutterende
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar, Odisha, Indien, 751001
- Aktiv, ikke rekrutterende
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indien, 600031
- Rekruttering
- ICMR - National Institute for Research in Tuberculosis
-
Kontakt:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- Telefonnummer: 044 2836 9537
- E-mail: bhavani.pk@icmr.gov.in
-
Kontakt:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Telefonnummer: 044 2836 9518
- E-mail: narendra.ng@icmr.gov.in
-
Ledende efterforsker:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
Ledende efterforsker:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
Underforsker:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500038
- Rekruttering
- Govt. General and Chest Hospital, Osmania Medical College
-
Kontakt:
- Dr V Karthik, MBBS., MD
- Telefonnummer: 04083814421
- E-mail: vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra, Uttar Pradesh, Indien, 282002
- Rekruttering
- Sarojini Naidu Medical College
-
Kontakt:
- Dr Gajendra Vikram Singh, MBBS., MD
- Telefonnummer: 0562 2260353
- E-mail: drsinghgv@gmail.com
-
Allahābād, Uttar Pradesh, Indien, 211002
- Rekruttering
- Moti Lal Nehru Medical College
-
Kontakt:
- Dr Amitabh Das Shukla, MBBS., MD
- Telefonnummer: 0532 261 3592
- E-mail: adshukla1977@gmail.com
-
Lucknow, Uttar Pradesh, Indien, 226003
- Rekruttering
- King George Medical University
-
Kontakt:
- Dr Rajiv Garg, MBBS., MD
- Telefonnummer: 0522 2255167
- E-mail: rajivkgmc@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: 2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Eksperimentel: 2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Eksperimentel: 2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
Aktiv komparator: 2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Tidsramme: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
Tidsramme: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Tidsramme: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Tidsramme: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Tidsramme: At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
Tidsramme: Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
- Ledende efterforsker: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis
Publikationer og nyttige links
Generelle publikationer
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Luftvejsinfektioner
- Infektioner
- Luftvejssygdomme
- Lungesygdomme
- Gram-positive bakterielle infektioner
- Bakterielle infektioner
- Bakterielle infektioner og mykoser
- Actinomycetales infektioner
- Mycobacterium infektioner
- Tuberkulose
- Tuberkulose, lunge
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Terapeutik
- Evalueringsmekanismer til sundhedsvæsenet
- Sundhedskvalitet
- Polycykliske forbindelser
- Heterocykliske forbindelser, 4 eller flere ringe
- Rifamycins
- Lactams, makrocyklisk
- Makrocykliske forbindelser
- Fluoroquinoloner
- 4-quinolones
- Quinolones
- Quinoliner
- Ofloxacin
- Epidemiologiske undersøgelsesegenskaber
- Rifampin
- Levofloxacin
- Kliniske protokoller
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2025 011
- CTRI/2026/02/102698 (Registry Identifier: CLINICAL TRIALS REGISTRY - INDIA)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .